Dymista filed with the FDA

A New Drug Application for a novel formulation of azelastine hydrochloride and fluticasone propionate, tentatively named “Dymista”, has been submitted to the U.S. Food and Drug Administration (FDA). Dymista (also known as MP29-02 in clinical trials), is a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.

Efficacy and safety of Dymista has been documented in several studies involving over 4,000 patients, including a long term safety study with more than 600 patients.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.


Documents & Links